Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

por Zabriskie, M S, Eide, C A, Yan, D, Vellore, N A, Pomicter, A D, Savage, S L, Druker, B J, Deininger, M W, O'Hare, T
Publicado 2016